Your Weight Loss & Fitness Authority
Research for ‘New weight-loss drug without muscle loss’ is increasingly focused on reducing body fat while preserving muscle. Losing weight is not always the same as losing body fat. Some people taking modern weight-loss medicines can lose lean mass along with fat. That has increased interest in treatments that could target body fat while doing … Read more
New study reveals lifelong use of weight-loss drugs like Mounjaro and Wegovy may be necessary A New Study Offers Clues About Why GLP-1 Weight Loss Varies Wegovy and Mounjaro have changed the way doctors approach obesity treatment. Yet one question remains common: why do some people lose much more weight than others on these medications? … Read more
Eli Lilly’s Retatrutide Hits Record Weight Loss, Challenges Surgery Efficacy | Whalesbook Retatrutide Is Producing Remarkable Weight-Loss Results The next generation of obesity medicines is moving quickly. One of the most closely watched candidates is retatrutide for weight loss, an experimental drug being developed by Eli Lilly. In May 2026, Lilly reported Phase 3 TRIUMPH-1 … Read more
FDA Approves New High-Dose of Wegovy HD 7.2 mg On March 19, 2026, the U.S. Food and Drug Administration approved Wegovy HD, a 7.2 mg once-weekly injectable dose of semaglutide, for certain adults with obesity or overweight plus at least one weight-related condition. The higher dose gives eligible patients another treatment option when clinically appropriate. … Read more
Foundayo(orforglipron) has moved from the clinical-trial stage into real-world U.S. obesity treatment. On April 1, 2026, the U.S. Food and Drug Administration approved Foundayo (orforglipron), an oral GLP-1 receptor agonist developed by Eli Lilly. It is approved for adults with obesity, or adults who are overweight and have at least one weight-related medical condition, when … Read more
GLP-1 drugs in 2026: More people without diabetes use drugs for weight loss GLP-1 medicines have changed how doctors approach obesity, type 2 diabetes and several related health problems. Drugs such as Wegovy, Ozempic and other GLP-1-based treatments can reduce appetite, improve blood sugar control and help many people lose significant amounts of weight. But … Read more
New weight-loss drugs 2026 and obesity treatments Originally published May 18, 2026. Updated August 19, 2026, with revised U.S. FDA approval information, clinical-trial developments, references, and FAQs. Introduction The world of weight-loss medicine is changing faster than ever before. A new generation of obesity medications is showing results in clinical trials that could reshape how … Read more
Multiple research studies have found that individuals using GLP-1 medications experienced greater weight loss, in addition to reductions in their insulin and testosterone levels. Recent studies indicate that GLP-1 drugs, which are already commonly utilized for weight control, might also benefit women suffering from polyendocrine metabolic ovarian syndrome (PMOS), previously recognized as polycystic ovary syndrome … Read more
